Foresite Capital Management VI LLC Buys Shares of 420,000 Structure Therapeutics Inc. (NASDAQ:GPCR)

Foresite Capital Management VI LLC acquired a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 420,000 shares of the company's stock, valued at approximately $11,390,000. Structure Therapeutics comprises about 5.1% of Foresite Capital Management VI LLC's investment portfolio, making the stock its 7th biggest holding. Foresite Capital Management VI LLC owned about 0.73% of Structure Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in GPCR. Boothbay Fund Management LLC lifted its holdings in shares of Structure Therapeutics by 147.0% in the fourth quarter. Boothbay Fund Management LLC now owns 83,148 shares of the company's stock valued at $2,255,000 after buying an additional 49,485 shares during the period. Virtus ETF Advisers LLC grew its position in Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares in the last quarter. Silverarc Capital Management LLC grew its holdings in shares of Structure Therapeutics by 116.1% during the 4th quarter. Silverarc Capital Management LLC now owns 152,395 shares of the company's stock valued at $4,133,000 after acquiring an additional 81,879 shares in the last quarter. Rock Springs Capital Management LP raised its stake in shares of Structure Therapeutics by 1.6% during the 4th quarter. Rock Springs Capital Management LP now owns 1,080,963 shares of the company's stock worth $29,316,000 after purchasing an additional 17,053 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Structure Therapeutics by 673.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock worth $111,000 after buying an additional 3,549 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Trading Down 0.9 %

Shares of Structure Therapeutics stock traded down $0.24 during midday trading on Friday, reaching $27.09. The company had a trading volume of 739,741 shares, compared to its average volume of 919,757. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -36.61 and a beta of -1.35. The stock has a fifty day simple moving average of $20.40 and a 200 day simple moving average of $27.52. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. Sell-side analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. William Blair started coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 target price for the company. Citigroup began coverage on shares of Structure Therapeutics in a research note on Friday. They set a "buy" rating and a $60.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $78.63.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.